Indian stocks: Visit www.stage2stocks.com →

Adaptive Biotechnologies Corporation

Stage 2 · Advancing · week 16

As of Oct 22, 2026, Adaptive Biotechnologies is in Stage 2, the uptrend phase, now in week 16 (since Jul 1, 2026). It closed at $24.41, 18.2% below its 52-week high and above its 200-day average, which is rising.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. More about the company

$24.41
-3.63% today
$3.9B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is ADPT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 19w
S4 18w
S2 37w
S2 41w
S2 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 19w → S1 4w → S4 18w → S1 10w → S2 37w → S3 2w → S2 41w → S3 7w → S4 8w → S1 3w → S2 16w current
Total tracked: 166 weeks across 12 stage runs.

ADPT among Diagnostics & Research12th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…12ADPTStage 2 · wk 1682−12.5%
vs 52W High
-18.2%
$12.41 lo$29.84 hi
18.2% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 16
1w13w26w
Week 16, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
26.4%
200 DMA: $19.30 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.60x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-12.5%
3M
+9.6%
6M
+76.6%
YTD
+53.4%
1Y
+40.7%
Scan Membership
Breakout Watch
Latest: 2025-05-13
5 appearances in last 60 days. First seen: 2020-06-01.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 16 · Vol 0.60x
2026-10-21S2
Wk 16 · Vol 0.71x
2026-10-20S2
Wk 16 · Vol 0.58x
2026-10-19S2
Wk 16 · Vol 0.55x
2026-10-16S2
Wk 16 · Vol 0.89x
2026-10-15S2
Wk 15 · Vol 0.79x
2026-10-14S2
Wk 15 · Vol 0.84x
2026-10-13S2
Wk 15 · Vol 0.87x
2026-10-12S2
Wk 15 · Vol 1.39x
2026-10-09S2
Wk 15 · Vol 0.66x
2026-10-08S2
Wk 14 · Vol 1.14x
2026-10-07S2
Wk 14 · Vol 0.91x
Moving averages & range
50 DMA
$26.12
200 DMA
$19.30
52W High
$29.84
52W Low
$12.41
5D Low
$23.95
Resistance levels (recent highs)
20d High
$29.84
60d High
$29.84
120d High
$29.84
250d High
$29.84
Next resistance
+22.2%
to 20d High
ROE
-38.8%
Profit margin -20.7%
Dividend Yield
0.00%
P/B 27.2

Adaptive Biotechnologies: quick answers

What stage is Adaptive Biotechnologies in?

As of Oct 22, 2026, Adaptive Biotechnologies (ADPT) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 1, 2026 and is in week 16. What the four stages mean

Is Adaptive Biotechnologies in an uptrend?

Yes. Adaptive Biotechnologies is in a Stage 2 uptrend. It trades 26.4% above its 200-day average, which is rising.

How far is Adaptive Biotechnologies from its 52-week high?

Adaptive Biotechnologies closed at $24.41 on Oct 22, 2026, 18.2% below its 52-week high of $29.84. Its 52-week low is $12.41.

How has Adaptive Biotechnologies performed over the past year?

As of Oct 22, 2026, Adaptive Biotechnologies is up 40.7% over the past year and up 53.4% so far in 2026.

Which sector and industry is Adaptive Biotechnologies in?

Adaptive Biotechnologies is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.